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NeuroimagingAlzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all cases [Hebert et al.,
2003, 1]. The need for effective therapies for AD is great. Current approaches, including cholinesterase inhib-
itors and N-methyl-D-aspartate (NMDA) receptor antagonists, are symptomatic treatments for AD but do not
prevent disease progression. Many diagnostic and therapeutic approaches to AD are currently changing due
to the knowledge that underlying pathology starts 10 to 20 years before clinical signs of dementia appear
[Holtzman et al., 2011, 2]. New therapies which focus on prevention or delay of the onset or cognitive
symptoms are needed. Recent advances in the identiﬁcation of AD biomarkers now make it possible to
detect AD pathology in the preclinical stage of the disease, in cognitively normal (CN) individuals; this
biomarker data should be used in the selection of high-risk populations for clinical trials. In vivo visualization
of AD neuropathology and biological, biochemical or physiological conﬁrmation of the effects of treatment
likely will substantially improve development of novel pharmaceuticals. Positron emission tomography
(PET) is the leading neuroimaging tool to detect and provide quantitative measures of AD amyloid pathology
in vivo at the early stages and follow its course longitudinally. This article is part of a Special Issue entitled:
Imaging Brain Aging and Neurodegenerative disease.
© 2011 Elsevier B.V. All rights reserved.1. Aβ metabolism
Although the exact cause-and-effect relations in AD are not well
understood, several potential underlying abnormalities have been
suggested including increased production, misfolding and deposition
of proteins; disruption of receptor and neurotransmitter state;
changes in synaptic density and functioning; and eventually degener-
ation and death of neurons with resultant brain atrophy [3–6].
Pathologically, AD primarily is characterized by the presence of
two abnormal proteins in the aggregated state: extracellular plaques
composed of beta-amyloid (Aβ) and intraneuronal neuroﬁbrillary
tangles (NFTs) composed of hyperphosphorylated tau [7]. The Aβ
peptide is cleaved by different secretases from the transmembrane
protein amyloid precursor protein (APP). When normally soluble Aβ
proteins reach a critical concentration, they become insoluble, mis-
fold, and aggregate in the form of Aβ plaques. Distinct plaque sub-
types have been identiﬁed: those with low (diffuse plaques) and
high (cored or neuritic plaques) proportion of ﬁbrillar componentsBrain Aging and Neurodegen-
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ris).
l rights reserved.[8]. Insoluble Aβ exceeds soluble forms of Aβ by a factor of about
100-fold in AD brain [9]. Studies of immunotherapies in transgenic
mice [10,11] and autopsy studies of humans treated with active im-
munization in the AN-1792 trial [12–14] indicate that Aβ in ﬁbrillar
plaques can be mobilized and cleared.
Plaques are composed of insoluble Aβ peptides, mostly 42 amino
acids in length (Aβ-42) [15]. It is possible that the small aggregated
oligomeric forms of Aβ-42, rather than ﬁbrils or plaques, are the key
pathological substrates [16].
It should be noted that in rare cases of AD, genetic alterations in-
crease the production of Aβ [17]. However, impaired clearance of
Aβmay cause late-onset AD through interactions with apolipoprotein
E (APOE) ε4, decreased catabolism of Aβ through reduced proteolysis,
impaired transport across the blood-brain barrier, or impaired CSF
transport [18].
2. Aβ cascade hypothesis
Characterization of the initial deposition of Aβ plaques is impor-
tant to improve our understanding of the pathology of early AD. The
amyloid-cascade hypothesis suggests that APP mismetabolism and
subsequent Aβ aggregation are the primary events driving AD patho-
genesis [19–21]. High levels of Aβ subsequently lead to a series of
downstream pathological events, including the production of exten-
sive intracellular NFT deposits, inﬂammation, oxidative stress, excito-
toxicity, loss of synaptic connections, and cell death, which cause the
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volved [2,22–24]. Mutations in the Aβ precursor protein gene on
chromosome 21, all lying in or near the Aβ peptide region, cause
early-onset, autosomal dominant familial forms of AD [25–27].
Presenilin-1 [28] and presenilin-2 [29] are other two genes that en-
code highly homologous transmembrane proteins, in which multi-
ple mutations have been identiﬁed in familial early-onset and late-
onset AD [30]. In addition to potentially harmful effects of Aβ for
brain cells [31], increased synaptic activity can elevate soluble Aβ
levels [32] and neural activity can change levels of APP [33], which
suggests that Aβ production and soluble levels may be in a dynamic
equilibrium state.
A close relationship between synaptic activity, brain metabo-
lism and Aβ deposition has been recently advocated by the results
of a study which observed a high spatial correlation between the
pattern of Aβ deposition in patients with dementia of Alzheimer
type (DAT) patients and the pattern of aerobic glycolysis mea-
sured using combined glucose and oxygen metabolism PET studies
in healthy young adults [34]. These data indicate that when Aβ ac-
cumulates in the human brain in AD, it does so in a distribution
that closely mirrors that of elevated aerobic glycolysis in the rest-
ing state of healthy young adults [34,35]. A strong correlation be-
tween aerobic glycolysis and Aβ deposition was demonstrated not
only in DAT patients but also in CN individuals with abnormally
elevated levels of Aβ, which indicate that these CN individuals
may be at the earlier stage of pathological processes seen in the
DAT group [34], the stage which is considered to represent pre-
clinical AD [36].
Even if Aβ is not the only or even the main causal event in AD pa-
thology, the deposition of Aβ is likely important for signifying the be-
ginning of the pathological cascade. Since all young healthy persons
and many CN older individuals have no evidence of Aβ deposition,
the conversion of a non-demented person from no evidence of Aβ
plaques to Aβ deposits in a cerebral distribution corresponding to
that seen in advanced DAT suggests a pathological event. We believe
that the pathological cascade may eventually become irreversible and
independent of the availability and level of Aβ, however we do not
know at what stage of AD this irreversibility may be achieved. Thus,
it is critical to ﬁnd better tools for determination of optimal timing
for interventions aimed on decreasing Aβ level and especially those
which may prevent irreversibility and further progression of patho-
logical cascade.
3. Biomarkers of AD
Biomarkers provide unique, biologicalmeasure of the underlyingpa-
thology independent of clinical signs and neuropsychological character-
istics of AD, and identiﬁcation of reliable biomarkers is critical for
evaluation of the preclinical/asymptomatic state of the AD. To date,
themostwidely studied and best validated biomarkers include cerebro-
spinal ﬂuid (CSF) assays of Aβ and tau, and amyloid imaging with
N-methyl-[11C]2-(4=-methylaminophenyl)-6-hydroxybenzothiazole
(Pittsburgh Compound B, or [11C]PIB) [2,37–39]. In addition, decreased
glucose metabolism in temporal and parietal cortex is considered as a
biomarker of synaptic dysfunction. Similarly, brain atrophy in themedi-
al temporal lobes, paralimbic, temporal and parietal cortex on struc-
tural MRI is a biomarker of AD-related neurodegeneration. Recently a
biomarker model has been recently proposed which suggests an or-
dered manner of abnormalities of these biomarkers which parallels
the hypothetical pathophysiological sequence of AD and is particularly
relevant to tracking the preclinical stages of AD [39,40].
Levels of CSF Aβ42 are commonly decreased in patients with AD
[41]. In a study comparing ﬂuid and imaging measures of potential
preclinical biomarkers of AD pathology, a robust relationship was ob-
served between cortical [11C]PIB binding and levels of CSF Aβ42 in CN
individuals [42,43]. Individuals with high cortical Aβ as detected by[11C] PIB PET had low CSF Aβ42 whereas those without cortical Aβ
had high Aβ42. These ﬁndings suggest that a low CSF Aβ42 level is
a sensitive marker of Aβ deposition in the brain regardless of the
state of AD.
It should be noted that decreased CSF Aβ42 levels have also been
reported in frontotemporal dementia, vascular dementia, Creutz-
feldt–Jacob disease and dementia with Lewy bodies [44–46]. Potential
limitation of AD studies that have used CSF Aβ42 is the lack of stan-
dardization for Aβ quantiﬁcation. Little is known about the CSF
Aβ42 turnover and clearance in normal aging, and known circadian
ﬂuctuations of CSF Aβ42 levels [47] may possibly contribute to the
variability of results. Levels of CSF Aβ42 do not correlate well with
AD duration or severity [48], which is consistent with Aβ imaging
data of little changes in Aβ accumulation in clinical AD [49] and
may suggest that amyloid pathology occurs very early in course of
the disease but may have stabilized by the clinical manifestations of
DAT.
Increased levels of CSF tau may indicate neuronal injury frommul-
tiple causes and were seen in AD patients [41,45,48,50–52] as well as
in frontotemporal dementia, stroke and Creutzfeldt–Jacob disease
[51]. In preclinical AD, CSF tau levels are correlated with the amount
of Aβ deposition [43]. Higher concentrations of CSF tau are associated
with greater cognitive impairment in preclinical and clinical AD [53].
In AD, tau undergoes abnormal hyperphosphorylation and phosphor-
ylated tau (p-tau) may offer equivalent if not better diagnostic utility
for AD than total tau. Various phosphorylated epitopes may be effec-
tive in differentiating AD patients from controls [54], and p-tau231
appears to provide diagnostic speciﬁcity for AD and to improve the
differentiation between AD and frontotemporal dementia [55],
while p-tau181 helps the differentiation between AD and dementia
with Lewy bodies [54].
The ratios of CSF tau/Aβ42 and p-tau/Aβ42 in CN individuals
strongly predict progression to clinical state of AD. Over 3–4 years
of follow-up, 70% of individuals with elevated tau/Aβ42 ratios be-
came clinically positive in one study [52], and another study demon-
strated that all individuals who converted to mild cognitive
impairment had elevated tau/Aβ42 ratios [56].
4. Aβ tracers
With the development of positron emission tomography (PET) ra-
diotracers with high in vivo binding to Aβ plaques it is now possible
to quantify pathological changes in the human brain that were previ-
ously restricted to post-mortem studies. Ideally, Aβ tracers should: 1)
effectively image brain Aβ deposition; 2) have good reproducibility
across many subjects and clinical settings; and 3) be widely accessible
and appropriate for the particular task [57]. Only a few current tracers
satisfy these requirements; however, new tracers for Aβ imaging are
under development.
As the comparative review of chemistry of Aβ-speciﬁc 11C and 18F
PET radiopharmaceuticals has been recently provided by others
[58,59], we will present very brieﬂy characteristics of known radio-
tracers and focus our discussion on the existing PET imaging data in
preclinical AD.
[18F]FDDNP [60] was the ﬁrst reported PET tracer to image AD pa-
thology in vivo. A higher retention of the compound was demonstrat-
ed in hippocampus, amygdala and enthorhinal cortex of individuals
with symptomatic AD compared with CN persons [61]. However,
[18F]FDDNP has relatively high non-speciﬁc binding although it may
also bind to tau protein [62–64]. The stilbene 4-N-[11C-methyl]
amino-4′-hydroxystilbene ([11C] SB-13) has been proposed as a com-
pound with high afﬁnity for Aβ, high initial brain uptake and relative-
ly rapid washout from normal rat brain after an intravenous injection,
however it has relatively higher uptake in healthy individuals [65,66].
Recently, several 18F-labeled tracers in addition to FDDNP were
designed and are currently under study including ﬂorbetapir ([18F]
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[63,67–69]. [18F] BAY94-9172 demonstrated neocortical binding in
AD patients which was greater in precuneus/posterior cingulate and
frontal cortex than in lateral temporal and parietal cortex, with rela-
tive sparing of occipital, sensorimotor and medial temporal cortex.
At 90–120 min after injection, higher neocortical SUVR was observed
in AD patients compared to healthy controls or patients with fronto-
temporal lobar degeneration. Visual interpretation was 100% sensi-
tive and 90% speciﬁc for detection of AD [67]. It has been suggested
that further validation of [18F] BAY94-9172 is required in order to
evaluate better the kinetics and metabolism of the tracer and deter-
mine appropriate quantiﬁcation method [67].
[18F] AV-45 has high binding afﬁnity, as demonstrated by in vitro
binding studies using AD brain homogenates; high selective Aβ pla-
que labeling, as demonstrated by in vitro autoradiography using
post-mortem AD brain sections; and excellent brain penetration and
rapid kinetics in healthy mice and nonhuman primates [70–72]. The
radiochemistry of [18F] AV-45 has been optimized to make this proce-
dure simpler and more convenient and suitable for routine produc-
tion and distribution of this radiopharmaceutical [71,72]. In humans,
[18F] AV-45 is well tolerated and it shows signiﬁcant discrimination
between AD patients and healthy controls [73]. It is rapidly cleared
from circulation, and maximum uptake occurs approximately 30 mi-
nutes after injection and remains essentially unchanged for the sub-
sequent 60 minutes [73], providing enough time to obtain a 10-min
image. The dosimetry of [18F] AV-45 is suitable for clinical and re-
search applications including longitudinal studies of Aβ accumulation
[74]. No evidence of elevated Aβ deposition with [18F] AV-45 was
demonstrated in CN individuals within the age range of 18 and
50 years, regardless of APOE genotype [75]. [18F] AV-45 imaging in
multicenter study was correlated with the presence and density of
Aβ at autopsy, and more studies are ongoing to evaluate this marker
in the clinical diagnosis of AD and for the prediction of progression to
dementia [75]. Aβ tracers also have been proposed for single photon
emission tomography, including 123I-IMPY and 125I aurone deriva-
tives [76–79].
5. [11C] PIB PET
[11C]PIB currently is the most studied and used tracer for PET im-
aging of cerebral Aβ pathology in vivo [80,81]. Signiﬁcantly higher ce-
rebral binding of [11C]PIB has been demonstrated in a speciﬁc pattern
in the individuals with symptomatic AD patients compared with CN
older adults [49,82–84] (Fig. 1). [11C] PIB is selective for ﬁbrillar Aβ
with high afﬁnity to a single binding site in homogenates from AD
brains [85,86] and minimal binding to cerebellum. Therefore, stan-
dard uptake values, corrected by using the cerebellum as reference
region, provide reproducible results with a scanning time of
60–90 min [85]. Methodology and radiation dosimetry for quantita-
tion of [11C] PIB uptake has been documented [87,88]. [11C] PIB
brain uptake may be quantiﬁed using distribution volume ratios
(DVR) or binding potentials (BP) obtained with the Logan graphic
method using the cerebellum as the reference region, or it may be
assessed using some standardized uptake value ratio (SUVR), which
is analyzed manually or with automatic algorithm and usually repre-
sents the ratio of [11C] PIB accumulation in particular cortical region
to [11C] PIB retention in the whole brain [84,89–92]. Recently, an
image-derived input function approach was proposed for quantita-
tive assessment of [11C] PIB retention without arterial sampling [93]
and other techniques are under development.
Regional analysis is usually provided with manually deﬁned re-
gions of interests (ROIs) using co-registered MR image [84,85,94];
and semi-automatic and automatic [95] or voxel-wise (SPM) analysis
may also be used [90]. Various ROIs and global means of representa-
tive cortical regions are used by different centers. In our university,
we deﬁne mean cortical binding potential (MCBP) calculated fromthe mean of the binding potential values in the prefrontal cortex,
gyrus rectus, lateral temporal, and precuneus regions [42,84,96,97].
Others use mean cortical DVR averaged from frontal, anterior cingu-
late, precuneus, lateral temporal, and parietal cortex and striatum
[94] or calculate mean DVR from manually drawn orbitofrontal, pre-
frontal, superior frontal, parietal, lateral temporal, occipital, and ante-
rior and posterior cingulate regions [98]. Average cortical SUVR may
also be calculated from area-weighted mean of frontal, superior pari-
etal, lateral temporal, lateral occipital, and anterior and posterior cin-
gulate regions [95]. Although there is some consensus between
various centers regarding these regions, variations in ROIs and proto-
cols for manually drawn regions make cross-center comparisons dif-
ﬁcult. A standardized, automated approach with full, accurate
segmentation of the brain is still needed in the ﬁeld. A promising ap-
proach is the use of the FreeSurfer (http://surfer.nmr.mgh.harvard.
edu), a set of automated tools for reconstruction of the brain's cortical
surface from structural MRI data, to create multiple standard regions
of interests and facilitate the quantitative regional analysis of PET im-
ages. FreeSurfer automatically segments and parcellates T1-weighted
brain MR images [99–101] and create distinct regions in cortical and
subcortical gray matter, which then can be applied to co-registered
PET images of the same individual. It has been used in neuroimaging
studies including AD research for the analyses of the volumetric
changes [102–105], functional MRI data [106], and it has a good po-
tential for [11C] PIB PET [107].[11C]PIB binding to Aβ has been validat-
ed by comparison to additional post-mortem quantitative assays, a
limited number of autopsy correlations [108,109], and a unique corre-
lation between [11C] PIB PET imaging and brain biopsy in 10 patients
who had [11C] PIB scanning prior to shunt placement [110]. Excellent
agreement existed between levels of [11C] PIB PET uptake and Aβ
quantitation in the post-mortem regions [108]. The biopsy study
showed high correlation with Pearson r=0.85 and very good agree-
ment in 9 of 10 biopsies [110]. However, in one biopsy there was ev-
idence of Aβ by histology but when the [11C] PIB PET scan was done
(after a period of 20 months) there was no elevated [11C] PIB uptake
in the brain region. There is no clear explanation for this apparent
“false-negative” [11C] PIB PET scan, in view of the excellent correla-
tion of [11C] PIB and Aβ in the other subjects.
[11C] PIB has been shown to bind speciﬁcally to Aβ-40 and Aβ-42
synthetic ﬁbrils and insoluble Aβ plaques containing Aβ-42 and Aβ-
40 found in AD brain [108,111]. In contrast, [11C] PIB does not bind ap-
preciably to soluble Aβ and probably does not bind to oligomeric
forms of Aβ nor to nonﬁbrillar plaques until they reach some critical
size (yet to be determined). [11C] PIB binding requires an extended
Aβ pleated sheet structure found in Aβ ﬁbrils and plaques in order to
bind with high afﬁnity. The binding of the tracer [11C]PIB to NFTs has
been previously evaluated and is regarded as negligible [112,113].
However, Johnson et al. [114] demonstrated substantially increased
[11C]PIB binding in the occipital cortex of patients with cerebral amy-
loid angiopathy. 18F-labeled PIB analogues have been synthesized re-
cently and are under experimental evaluations now [115,116].
6. Aβ imaging in preclinical AD
The concept of preclinical AD postulates that AD lesions accumu-
late in the brain for years prior to appearance of cognitive deﬁcits or
symptoms of dementia [36]. Preclinical AD assumes that AD patholo-
gy in CN individuals ultimately culminates in progressive neuronal
deterioration that results in the clinical manifestations of DAT, al-
though the time to DAT may differ depending on reserve capacities
of an individual [117–119]. It is possible that some individuals with
presumptive preclinical AD may never develop DAT, no matter how
long they live.
Post-mortem morphometric analysis of lesion densities in individ-
uals age 54 to 89 years of age who were CN in life or who had very
mild DAT or advanced DAT found that large densities of senile plaques
Fig. 1.Mean MRI and PET [11C]PIB distribution in a standard atlas coordinate system from 10 subjects with dementia of the Alzheimer type. PET data represent [11C]PIB activity in
the late (30 to 60 min after injection) distribution and has been normalized to standardize display and increase contrast. Brain areas used to detect raised [11C] PIB uptake in non-
demented subjects are indicated with arrows. PFC=prefrontal cortex; Temp=temporal cortex; Precun=precuneus region. Reproduced with permission from Ref. [84].
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Fig. 2. Schematic maps showing [11C] PIB BP distribution on lateral and medial cortical
surfaces of the left (L) and right (R) hemispheres of the human brain. A, Healthy young
(b50 y. o.) adults; B–D, Cognitively normal older (>50 y. o.) adults with low (B), mod-
erate (C) and high (D) Aβ deposition; E, Individuals with dementia of Alzheimer's type
(modiﬁed with permission from Ref. [34]).
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mented cases and in 31% of CN individuals, while NFTs were restricted
in the CN individuals to the parahippocampal gyrus and hippocampal
ﬁeld CA1 [120]. These observations were extended in subsequent re-
ports [4,121,122], concluding that the cerebral deposition of amyloid
in the form of Aβ plaques appears to accelerate an age-related tauopa-
thy and that the AD disease process beginswell before clinical detection
of dementia. Seven of 26 CN individuals older than age 75 had exten-
sively distributed neocortical diffuse and neuritic senile plaques in den-
sities sufﬁcient for a neuropathological diagnosis of AD, which was
interpreted as a preclinical stage of AD [4].
Current recommendations from the National Institute on Aging
and Alzheimer's Association workgroups are that both the underlying
pathological and pathophysiological process of AD and clinical symp-
toms should be best conceptualized as a continuum or a trajectory,
and that these processes may evolve in parallel but temporally offset
trajectories [39]. According to this concept, three staging categories
were deﬁned for preclinical AD research. Stage 1, “the stage of asymp-
tomatic cerebral amyloidosis”, implies biomarker evidence of Aβ ac-
cumulation with elevated PET tracer retention and/or low CSF Aβ42,
but no detectable evidence of additional brain alterations suggestive
of neurodegeneration or behavioral impairment. Stage 2, “amyloid pos-
itivity+evidence of synaptic dysfunction and/or early neurodegenera-
tion”, includes besides amyloid accumulation, presence of one or more
markers of downstream neuronal injury related to AD pathology, in-
cluding elevated CSF tau or phospho-tau, decreased FDG uptake and
cortical thinning/atrophy in AD-prone cortical regions. Stage 3, “amy-
loid positivity+evidence of neurodegeneration+subtle cognitive de-
cline”, is characterized, besides evidence of Aβ accumulation and
neurodegeneration, by appearance of subtle cognitive decline and
approaching the border zone with the proposed clinical criteria for
mild cognitive impairment [39].
Imaging and molecular biomarkers for AD now identify in vivo
correlates of neuropathological AD and may be used as markers of
preclinical AD. Abnormally elevated [11C]PIB uptake in what has
been considered ”healthy aging” has been consistently demonstrated
from very early [11C]PIB studies and it is likely an important in vivo
pathological hallmark of preclinical AD. In the initial report by
Klunk et al. [80], elevated PIB uptake was seen in 1 of the 6 CN
older controls. In a subsequent study [84], 4 of the 23 subjects over
65 years had elevated PIB uptake. Later Pike et al. [123] identiﬁed
22% of the 32 CN controls and Aizenstein et al. [94] reported 21% of
43 clinically unimpaired elderly persons as having Aβ plaques. Higher
frequency (30–33%) of elevated [11C]PIB BP in CN adults especially in
older individuals are observed in recent studies involving larger co-
horts, and these percentages are comparable to age-related frequency
of neuropathological AD on post-mortem examination of CN adults
[96,124,125].
The spatial distribution of [11C] PIB uptake in CN older individuals
is similar to AD individuals and is elevated in the posterior cingulate,
precuneus, gyrus rectus, orbitofrontal, prefrontal and lateral temporal
cortex with relatively spared occipital and sensorimotor areas (Fig. 2)
[80,84,94,123,126]. The highest [11C] PIB BP of all gray matter regions
is noted in the posterior cingulate, precuneus and prefrontal cortex
[84,94,95,127]. CN individuals demonstrate similar or lower levels
of [11C] PIB uptake compared to mild cognitive impairment and DAT
[84,95].
Autosomal dominant AD attracts increasing attention, because it
allows evaluation of Aβ accumulation in young and middle-aged
adults with knownmutation years or decades before clinical manifes-
tations. [11C] PIB PET studies have revealed evidence of Aβ regional
deposition especially in precuneus, posterior cingulate and prefrontal
cortex, and in stratum, in carriers, including those who were up to
10 years younger than the age of onset for their family [128–130].
In longitudinal studies using [11C] PIB as an indicator for Aβ accu-
mulation, no or little increase in tracer uptake was found during1–3 years of follow-up in individuals with mild cognitive impairment
and DAT [82,131,132]. These ﬁndings indicate that brain Aβ accumu-
lates more rapidly in the early phases of AD and only very slowly in
the more advanced stages of the disease. Recent longitudinal [11C]
PIB studies demonstrated increase of Aβ accumulation over time in
CN individuals with elevated baseline levels of Aβ [95,98].
Sojkova et al. [98] reported longitudinal [11C] PIB DVR data in 14
older individuals with minimal and 10 with elevated initial Aβ accu-
mulation. The group with elevated mean cortical DVR showed signif-
icant 2.3% increase in Aβ accumulation compared to baseline, and all
4 individuals with three [11C] PIB studies demonstrated continuous
progression, which was linear in 3 cases of 4. Regionally, signiﬁcant
increases in [11C] PIB DVR were observed in the prefrontal, superior
frontal, parietal, lateral temporal, occipital, and anterior cingulate cor-
tex, and in the combined group of CN adults the highest annual in-
crease was demonstrated in posterior cingulate cortex. None of
these participants met the diagnostic criteria for mild cognitive im-
pairment (MCI), however 4 had CDR 0.5, and they all demonstrated
increases over time in global cortical and regional [11C] PIB DVR
[98]. The results indicate that overall magnitude of change may be de-
pendent on the duration of follow-up; with smaller changes resulting
from shorter follow-up. A low average rate of Aβ growth in a group
may be also due to individual variability, as some individuals demon-
strate substantial increases in Aβ accumulation over time, while
others, especially older individuals, may show no increases or even
decreases in [11C] PIB uptake.
Villemagne et al. [95] recently reported signiﬁcant increases in
mean cortical [11C] PIB SUVR after 20-month follow-up in DAT but
not in mild cognitive impairment or CN individuals. However CN par-
ticipants demonstrated more substantial increase after 38-month
follow-up compared to individuals with mild cognitive impairment
and DAT, and only CN individuals demonstrated signiﬁcant increase
in mean cortical and regional (orbitofrontal and dorsolateral prefron-
tal cortex) [11C] PIB SUVR between 20 and 38 months of follow-up
[95]. Objective cognitive impairment was demonstrated in 5 of 32
CN individuals with elevated baseline [11C] PIB SUVR at 20-month
follow-up and in 8 of 10 individuals who reached the 38-month
time point. These 8 individuals who demonstrated cognitive impair-
ment had signiﬁcantly lower memory scores, higher baseline [11C]
PIB SUVR, and higher [11C] PIB SUVR increases than those individuals
who did not progress. These data suggest initial rise and then plateau
in DAT individuals, but continuously progressive Aβ accumulation
with clinical worsening in CN individuals with high Aβ burden.
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risk factors for AD. The APOE ε4 allele is the major genetic susceptibil-
ity factor for late-onset AD, with an expressing gene dose-dependent
risk for the development of DAT at an earlier age of onset [133–135].
Other isoforms of APOE are considered to be neutral (APOE ε3) or
even protective (APOE ε2) for AD risk [136,137]. The increased risk
of APOE ε4 for AD may be mediated by disturbances in cerebral Aβ
metabolism [138–140]. There is isoform-dependent propensity
(ε4>ε3>ε2) for Aβ deposition in experimental animals [141,142],
and in humans [96]. APOE ε4 carriers have increased cerebral amyloid
deposition compared to non-carriers [143–145]. The role of APOE ε4
in promoting AD appears to be directly related to its effect on AD pa-
thology, because its association with clinically diagnosed DAT is non-
signiﬁcant after controlling for the densities of senile plaques and
neuroﬁbrillary tangles in autopsied individuals [146]. Consistent
with this premise, an APOE genotype effect on Aβ load has been dem-
onstrated in individuals with moderate DAT [147] and in CN individ-
uals [96,124,126,148,149]. In a large cohort of CN individuals, APOE
ε4 demonstrated a powerful dose-dependent effect on cerebral Aβ
deposition as measured with [11C] PIB and on CSF levels of Aβ42,
but not tau or p-tau181 levels [96]. These data suggest that Aβ
abnormalities, but not tau abnormalities, initiate the pathological
cascade of preclinical AD.
Increasing evidence suggests that preclinical AD is not benign but
eventually produces sufﬁcient synaptic and neuronal damage to
cause cognitive decline and other symptoms of AD [36,150]. Reduced
levels of CSF Aβ42 in CN older adults are associated with whole brain
atrophy [151], and with hypometabolism in the medial temporal lobe
[152]. CN older individuals with elevated [11C]PIB binding levels also
demonstrate multiregional brain atrophy [153–155], cerebral cortical
thinning [156], aberrant default network activity and functional MRI
connectivity deﬁcits similar to AD [157–160], decreased task-
induced fMRI deactivation in the default network regions [161],
lower performance on a demanding test of associative memory re-
trieval [162], episodic memory deﬁcits [123,163], as well as longitudi-
nal cognitive decline [153]. CN individuals with elevated MCBP are at
signiﬁcantly greater risk of developing the symptomatic stages of AD
than individuals with less or no [11C]PIB retention [150]. Moreover,
this [11C]PIB predictive effect is restricted to symptomatic AD and
does not encompass non-DAT causes of mild dementia [150]. Ville-
magne et al. [95] reported that there is a 16% risk of developing
mild cognitive impairment or DAT over 20 months and 25% risk by
3 years in CN individuals with high [11C]PIB retention. Higher educa-
tional attainment [119] or socioeconomic status [164] may permit in-
dividuals with preclinical AD, as ascertained by [11C]PIB, to better
tolerate AD pathology without obvious cognitive deterioration, sug-
gesting that they have a greater reserve against the clinical expres-
sion of AD [165].
Recently it has been suggested that certain lifestyle practices such
as physical exercise could potentially deter or slow disease progres-
sion [166]. Physical exercise has been recognized as preserving not
only cardiovascular but also brain and cognitive health in older adults
[167]. It has been recommended by Alzheimer's Association to clini-
cians as a way to maintain cognitive functioning in AD and enhance
a patient's quality of life, and studies suggested that exercise may re-
duce risk of cognitive decline and dementia [168,169], and may have
beneﬁcial effects on AD-related pathology [170–173] including Aβ
deposition as measured with [11C]PIB PET [166].
Hinrichs et al. [97] recently studied the heritability of Aβ deposi-
tion as expressed by MCBP using [11C]PIB PET and demonstrated
that MCBP is a genetic trait with signiﬁcant unique variability and
that other Aβ related traits such as cerebrospinal ﬂuid Aβ42 or
APOE ε4 genotype do not fully explain the variance in MCBP. The pre-
dictive accuracy of MCBP alone for identiﬁcation of symptomatic AD
is quite high but it can be improved substantially when MCBP is
used together with other factors including education, normalizedwhole brain volume, physical health rating, gender and use of medi-
cations that may interfere with cognition [174].
7. Research and therapeutic directions in preclinical AD
Further directions include the need in carefully organized longitu-
dinal studies with multiple repeated imaging and other diagnostic as-
sessments. While substantial data has been collected in AD using
anatomical, metabolic and molecular imaging techniques, most data
is cross-sectional and those few longitudinal studies are limited in
number of participants and do not have enough temporal resolution
to characterize the onset and growth of Aβ plaques. More longitudi-
nal data is needed to demonstrate whether Aβ plaque levels stabilize
very quickly after appearing, or alternatively, there is a slow and
steady accumulation of Aβ plaques over a prolonged period of time.
Longitudinal studies are critical also for the development of a reliable
tool for documentation of the transfer from healthy aging to preclin-
ical AD. This conversion may be determined by some threshold level
of global Aβ deposition, but this arbitrarily approach should be eval-
uated in larger samples and validated by clinicopathological correla-
tions to better characterize the incidence of preclinical AD. Time of
conversion is very likely the most important period for the selection
for preventive treatment trials.
It should be noted that careful design of clinical trials to test
disease-modifying agents is critical, with largely enough sample
sizes and optimal parameters chosen to adequately power these tri-
als. Government and industry ofﬁcials as well as academia re-
searchers should consider the optimum use of the clinical trials
design for disease-modifying agents on AD in their effort to search
for the treatments with the potential to modify the underlying path-
ophysiology of AD [175]. Starting as early as possible before the ap-
pearance of cognitive symptoms, the preclinical stage of AD should
be a critical strategy for preventive therapies aimed on decreasing
production, increasing clearance, decreasing aggregation and remov-
ing aggregates of Aβ. It is likely that the metabolic changes in Aβ-
prone regions may actually begin at the same time as observed pla-
que development in CN subjects, suggesting neuronal dysfunction is
a very early part of the pathological cascade and there would be an in-
centive to begin treatment early as well.
Combining the efforts of multiple institutions and creating joint
databases of clinical and imaging information is of critical importance
for successful research and clinical efforts. A good example is the Alz-
heimer's Disease Neuroimaging Initiative (ADNI), a multicenter re-
search project that studies changes of cognition, brain structure and
function, and biomarkers in elderly healthy individuals, participants
with mild cognitive impairment and persons with symptomatic AD
with a major goal to determine and validate MRI, PET and CSF/blood
biomarkers as predictors and outcomes for use in clinical trials of
AD treatments[176–183].
Another good example is related to autosomal dominant AD, which,
representing less than 1% of all AD cases, may nevertheless be consid-
ered as one of the best populations for early preventive trials because
it allows treating asymptomatic young adults, not affected by other
brain diseases seen commonly in older individuals, and years or decades
before clinical onset [184]. Due to the geographically dispersed nature
of autosomal dominant families and relative rarity of the disease, an in-
ternational network of research centers, known as Dominantly Inher-
ited Alzheimer's Network (DIAN) has been established to enable
adequately powered longitudinal multicenter studies and clinical trials
in this unique and highly informative population [184].
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